Total Therapy Publications

Results of our Total Therapy trials have been published in well-respected, peer-reviewed journals. Citations from the past few years are included below, ordered from the most recent.

Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1.

Heuck C, Szymonifka J, Hansen E, Shaughnessy JD, Usmani S, Van Rhee F, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Bailey C, Epstein J, Hoering A, Crowley JJ, Barlogie B.

Clin Cancer Res. 2012 Aug 1.

            PMID: 22855579

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, Nair B, Alsayed Y, Vanrhee F, Barlogie B.

Leukemia. 2012 Jun 18. doi: 10.1038/leu.2012.160.

            PMID: 22705990

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.

Usmani SZ, Sexton R, Hoering A, Heuck CJ, Nair B, Waheed S, Alsayed Y, Chauhan N, Ahmad N, Atrash S, Petty N, van Rhee F, Crowley J, Barlogie B.

Blood. 2012 Jun 6.

            PMID: 22674807

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols.

Usmani SZ, Nair B, Qu P, Hansen E, Zhang Q, Petty N, Waheed S, Shaughnessy JD Jr, Alsayed Y, Heuck CJ, van Rhee F, Milner T, Hoering A, Szymonifka J, Sexton R, Sawyer J, Singh Z, Crowley J, Barlogie B.

Leukemia. 2012 Apr 17. doi: 10.1038/leu.2012.107.

            PMID: 22508408

International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols

Waheed S, Shaughnessy JD, van Rhee F, Alsayed Y, Nair B, Anaissie E, Szymonifka J, Hoering A, Crowley J, Barlogie B.

Cancer. 2011 Mar 1;117(5):1001-9. 

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Shaughnessy JD Jr, Hoering A, Crowley J, Barlogie B.

Blood. 2010 Aug 26;116(8):1220-7. 

Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms

Barlogie B, Anaissie E, van Rhee F, Shaughnessy JD Jr, Szymonifka J, Hoering A, Petty N, Crowley J.

J Clin Oncol. 2010 Jun 20;28(18):3023-7. 

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

Nair B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Szymonifka J, Hoering A, Alsayed Y, Waheed S, Crowley J, Barlogie B.

Blood. 2010 May 27;115(21):4168-73. 

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences

Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL.

J Clin Oncol. 2010 Mar 1;28(7):1209-14. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543. 

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.

Hoering A, Crowley J, Shaughnessy JD Jr, Hollmig K, Alsayed Y, Szymonifka J, Waheed S, Nair B, van Rhee F, Anaissie E, Barlogie B.

Blood. 2009 Aug 13;114(7):1299-305.

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.

Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K, Alsayed Y, Waheed S, Petty N, Epstein J, Shaughnessy JD Jr, Tricot G, Zangari M, Zeldis J, Barer S, Crowley J.

Blood. 2008 Oct 15;112(8):3115-21.

Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma.

Barlogie B, Anaissie E, Haessler J, van Rhee F, Pineda-Roman M, Hollmig K, Alsayed Y, Epstein J, Shaughnessy JD Jr, Crowley J.

Cancer. 2008 Jul 15;113(2):355-9.

Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs.

Barlogie B, Haessler J, Pineda-Roman M, Anaissie E, van Rhee F, Kiwan E, Steward D, Gurley J, Jenkins B, Crowley J.

Cancer. 2008 Jun 15;112(12):2720-5.

VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.

Pineda-Roman M, Zangari M, van Rhee F, Anaissie E, Szymonifka J, Hoering A, Petty N, Crowley J, Shaughnessy J, Epstein J, Barlogie B.

Leukemia. 2008 Jul;22(7):1419-27.

Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.

Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J, Shaughnessy JD Jr.

Br J Haematol. 2007 Jul;138(2):176-85.